Overview
This randomized, single-blind, controlled clinical trial aims to evaluate the effects of a topical curcumin spray on post-extraction wound healing and postoperative symptoms in adults undergoing first molar extraction. Participants will be randomly assigned to one of three groups: curcumin topical spray, 0.12% chlorhexidine topical spray, or standard postoperative care without a topical spray. The interventions will be applied twice daily for 7 days. Postoperative pain will be assessed using a visual analog scale, while wound healing will be evaluated using the Landry, Turnbull, and Howley Healing Index. Wound dimensions will also be recorded during follow-up. In addition, salivary levels of inflammatory biomarkers, including interleukin-1β (IL-1β), tumor necrosis factor-alpha (TNF-α), and prostaglandin E2 (PGE2), will be analyzed to assess the local inflammatory response during the postoperative healing period.The study aims to compare the clinical effects of topical curcumin with chlorhexidine and standard postoperative care during the early healing period after tooth extraction.
Description
This study is designed as a randomized, single-blind, three-arm controlled clinical trial to evaluate the effect of a curcumin-containing topical spray on early wound healing and postoperative symptoms following first molar extraction in adults aged 18-40 years.
Eligible participants requiring first molar extraction will undergo minimally traumatic tooth extraction without primary suturing. Following extraction, participants will be randomly allocated to one of three study groups. Participants in the curcumin group will use a Curcuma longa-containing topical spray, administered as two sprays to the extraction site twice daily for 7 days. Participants in the chlorhexidine group will use a 0.12% chlorhexidine topical spray according to the same administration schedule. Participants in the control group will receive standard postoperative care without the use of an additional topical spray.
All participants will receive standardized postoperative instructions. Clinical follow-up will be performed during the early postoperative healing period. Postoperative pain will be assessed using a 0-10 visual analog scale (VAS) on postoperative days 1, 3, 5, and 7. Soft-tissue wound healing will be evaluated using the Landry, Turnbull, and Howley Healing Index on postoperative days 7 and 14. Wound dimensions will be measured in the buccolingual and mesiodistal directions during follow-up.
In addition to clinical assessments, salivary inflammatory biomarkers, including interleukin-1 beta (IL-1β), tumor necrosis factor-alpha (TNF-α), and prostaglandin E2 (PGE2), will be analyzed to evaluate the local inflammatory response associated with postoperative healing.
The study will compare clinical healing, postoperative pain, wound dimensions, mouth opening, and inflammatory biomarker levels among the curcumin, chlorhexidine, and control groups. The aim is to determine whether topical curcumin influences early post-extraction wound healing and postoperative inflammatory symptoms compared with chlorhexidine and standard postoperative care.
Eligibility
Inclusion Criteria:
- Healthy individuals aged 18-40 years with ASA physical status I.
- Patients scheduled for extraction of a mandibular first molar.
- Individuals who voluntarily agree to participate and provide written informed consent.
- Individuals without chronic systemic disease and who do not use regular medication.
- Patients with no oral health condition that would contraindicate the surgical procedure.
Exclusion Criteria:
- Pregnant or breastfeeding individuals.
- Patients with systemic diseases or immunosuppression.
- Individuals with a history of previous surgery or trauma in the same region.
- Individuals with a known allergy or hypersensitivity to turmeric (curcumin), chlorhexidine spray, or any component of the study products.
- Individuals who smoke or consume alcohol.
- Individuals who regularly use medications, particularly anti-inflammatory or anticoagulant drugs.
